Today’s Research Reports on Stocks to Watch: Axovant Sciences and Heat Biologics

NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Axovant Sciences was one of the biggest gainers in the stock market on Wednesday after announcing that it has licensed an investigational gene therapy for Parkinson’s Disease from Oxford BioMedica. Shares of Heat Biologics also climbed a lot higher despite any news. The company’s CEO was said to present at the 2018 BIO International Convention on Wednesday.

RDI Initiates Coverage on:

Axovant Sciences Ltd.
https://rdinvesting.com/news/?ticker=AXON

Heat Biologics, Inc.
https://rdinvesting.com/news/?ticker=HTBX

Axovant Sciences Ltd. shares blew up on Wednesday to see a gain of 160% at the close. Trading volume at over 111 million shares was significant compared to the stock’s average trading volume of just under 1 million shares. The big breakout came after the company said it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, (an investigational gene therapy for Parkinson’s disease) from Oxford BioMedica. As part of the agreement, Oxford BioMedica will receive a $30 million upfront payment, $5 million of which will be applied as a credit against the process development work and clinical supply that Oxford BioMedica will provide to Axovant. Oxford Biomedica is also eligible to receive additional development, regulatory, and commercial milestone payments potentially in excess of $812 million. Axovant will fund all clinical development costs. Phase 1/2 dose escalation study of AXO-Lenti-PD in patients with advanced Parkinson’s is expected to commence by year-end. CEO Pavan Cheruvu, MD stated, “Axovant remains committed to developing innovative treatments for serious neurodegenerative conditions such as Parkinson’s disease, and we are excited to partner with Oxford BioMedica, a recognized global leader in cell and gene therapy. We are also pleased to welcome Fraser to our leadership team. He brings over two decades of experience in gene therapy manufacturing, and will be committed to building world-class gene therapy capabilities at Axovant. We will continue to pursue promising new therapeutic approaches based on transformative science, and will further expand our pipeline with high-quality assets like AXO-Lenti-PD. This is part of our long-term goal of building Axovant into a leader in the development and commercialization of innovative new medicines for neurological indications.”

Access RDI’s Axovant Sciences Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=AXON

Heat Biologics, Inc. shares closed up a little over 22% on Wednesday on nearly 4.9 million shares traded. There was no news from the biopharmaceutical company to explain the big jump but the company’s Chief Executive Officer, Jeff Wolf, was expected to present a corporate overview at the 2018 BIO International Convention yesterday. It was last month that Heat Biologics reported first quarter results. Mr. Jeff Wolf remarked at the time, “We had an eventful first quarter, with a number of positive clinical developments. Most notably, we announced positive interim results from our Phase 2 study investigating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®), in patients with advanced non-small cell lung cancer (NSCLC) whose cancers had progressed after treatment with one or more lines of therapy. These data are especially encouraging in patients with low levels of TIL and PD-L1, who are among the most difficult-to-treat patients. Importantly, we believe the data are consistent with the mechanism of action of our T-cell Activation Platform, which has been shown to promote a robust T-cell immune response. We believe the ability of our platform to convert ”cold tumors” to ”hot tumors” will be an important component in effective immunotherapy combinations against cancer.”

Access RDI’s Heat Biologics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=HTBX

Our Actionable Research on Axovant Sciences Ltd. (NASDAQ: AXON) and Heat Biologics, Inc. (NASDAQ: HTBX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 502006